Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden

Feb 27 2012

• By Cathy Dombrowski

Related Content

Regulatory Update For <em>Qnexa</em> Could Signal A Change In The Obesity Landscape

Jan 10 2012

Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs

Feb 07 2012

FDA Says <em>Qnexa</em> Needs CV Outcome Trial, Asks Cmte. To Consider Pre- Or Post-Approval Timeframe

Feb 17 2012

With SPA Finalized, Orexigen To Begin CV Outcomes Study For <em>Contrave</em> In Second Quarter

Feb 06 2012

NitroMed Looks To 2010 NDA For BiDil XR

Jan 16 2008

Qnexa May Get Staged Launch After No Vote From Advisory Panel

Jul 19 2010

REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel

Jul 19 2010

Related Companies

Vivus, Inc.

Johnson & Johnson

NitroMed, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Advisory Committees Risk Management Post Market Regulation & Studies Safety BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window